On February 25, 2026 Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage oncology company, reported that members of senior management will be participating in the following upcoming investor conferences in March.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen’s 46th Annual Health Care Conference
Format: Fireside Chat
Date and Time: Monday, March 2, 2026 at 3:50 p.m. ET
Location: Boston, MA

Leerink Global Healthcare Conference
Format: Fireside Chat
Date and Time: Monday, March 9, 2026 at 1:40 p.m. ET
Location: Miami, FL

Barclays 28th Annual Global Healthcare Conference
Format: 1×1 Meetings
Date: Tuesday, March 10, 2026
Location: Miami, FL

The Citizens Life Sciences Conference
Format: Fireside Chat
Date and Time: Wednesday, March 11, 2026 at 9:00 a.m. ET
Location: Miami, FL

Live webcasts of the fireside chats will be available on the investor relations page of the Terns Pharmaceuticals website at View Source A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations.

(Press release, Terns Pharmaceuticals, FEB 25, 2026, View Source [SID1234663017])

On February 25, 2026 BreezeBio, Inc., formerly known as GenEdit, reported the close of $60 million in Series B financing to advance its first internal therapeutic programs toward the clinic and to continue expansion of the company’s NanoGalaxy delivery platform. The new BreezeBio name reflects the company’s momentum in translating powerful delivery technologies into practical, scalable genetic medicines with curative potential.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Now that we can deliver genetic payloads to the right cells with precision, we are building genetic medicines designed to make a real difference for patients," said Kunwoo (Ryan) Lee, Ph.D., Chief Executive Officer of BreezeBio. "We’ve completed our transition from a delivery platform to a therapeutics company, and this financing allows us to advance our first internal programs toward the clinic while continuing to expand the reach of NanoGalaxy."

The company’s lead therapeutic candidate, BRZ-101, is a novel immune modulation therapy designed to restore tolerance in type 1 diabetes. The therapy delivers autoantigens encoded by mRNA and tolerogenic co-factors to antigen-presenting cells, which in turn present the antigens to T cells in the context of tolerance. The process induces antigen-specific regulatory T cells (Tregs) that block the autoimmune response precisely without affecting the functioning of the immune system. In preclinical testing, BRZ-101 induced antigen-specific immune tolerance in multiple models of autoimmune disease, including the NOD mouse model of diabetes, and was well tolerated in mice and non-human primates. The company is advancing BRZ-101 into IND-enabling studies.

"BreezeBio is solving one of the most significant challenges in gene therapy, targeted delivery, and in doing so is helping define the next generation of genetic medicines," said Vincent Jeong, Managing Director at Yuanta Investment, manager of the Ministry of Health, and lead investor in the Series B financing. "With platform validation through the company’s strategic collaboration and milestone achievement with a global biotech partner and clear progress toward clinical development, BreezeBio is approaching an important inflection point as it advances a differentiated internal pipeline designed to address significant unmet needs in autoimmune and other serious diseases. We believe BreezeBio is positioned to become a global genetic medicines developer, and Yuanta is committed to supporting that journey."

The engine for BreezeBio’s therapeutic programs is the company’s proprietary NanoGalaxy platform, which has demonstrated targeted delivery to the immune, cardiac, pulmonary, and central nervous systems based on the physiochemical properties of the polymers that encapsulate the payloads and form the nanoparticles. In addition, BreezeBio is expanding the platform with ligands conjugated to the nanoparticles for additional tissue and cell specificity, including delivery to T cells to enable in vivo CAR-T therapeutic development.

In parallel with its internal programs, BreezeBio continues to advance its multi-year collaboration and licensing agreement with Genentech, a member of the Roche Group. Following the initial milestone achievement and associated payment last year, R&D activities under the collaboration continue to progress.

The Series B financing is led by new investors, Yuanta Investment and DSC Investment, with participation from SV investment, Kiwoom Investment, STIC Ventures, Top Harvest Capital, and others. Existing investors, including DAYLI Partners, Pathway Investment, Loftyrock Investment, Korea Investment Partners, WOORI Venture Partners, KDB Silicon Valley, and ACVC Partners also participated.

(Press release, BreezeBio, FEB 25, 2026, View Source [SID1234663016])

On February 25, 2026 NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, reported the launch of RaDaR ST, its circulating tumor DNA (ctDNA) assay for detecting molecular residual disease (MRD).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"RaDaR ST represents an important advancement in MRD testing, a rapidly growing market that remains largely untapped," said Tony Zook, CEO of NeoGenomics. "By providing patient-specific molecular insights, the test enables clinicians to detect residual disease and recurrence sooner than conventional imaging, supporting more informed treatment decisions at each stage of care. Our goal with RaDaR ST is to give providers reliable, actionable results that can be incorporated into clinical practice and research programs, helping support informed clinical decisions and enable earlier intervention in patient care."

RaDaR ST uses patient-specific, tumor-informed panels to detect trace amounts of tumor DNA in blood, often before recurrence is visible on imaging. The assay combines whole-exome sequencing with advanced bioinformatics to track up to 48 tumor-specific variants with a limit of detection at 95% probability (LOD95) of 11 ppm, offering high sensitivity and specificity.*

Validated through a large and growing body of clinical and real-world data, including studies in breast and HPV-negative head and neck cancers, RaDaR ST shows utility for earlier detection of recurrence, identification of patients with persistent molecular disease, and long-term surveillance in high-risk populations. The assay is approved by Medicare for initial launch indications, with two additional indications submitted for reimbursement.

"These development milestones reflect the brisk pace of innovation across our portfolio and our ongoing commitment to investing in technologies that address emerging clinical needs," added Zook. "With the launch of RaDaR ST, NeoGenomics now offers a comprehensive solid tumor care solution that spans the continuum of cancer care from comprehensive diagnostic profiling to therapy selection and personalized MRD assessment, enabling physicians to better guide treatment decisions from diagnosis through long-term disease monitoring."

(Press release, NeoGenomics Laboratories, FEB 25, 2026, View Source [SID1234663015])

On February 25, 2026 Kivu Bioscience, Inc., a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers, reported the presentation of new preclinical data for KIVU-305, its CEACAM5-targeted ADC, at World ADC London 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Kivu also announced another significant milestone with receipt of Human Research Ethics Committee (HREC) approval and Clinical Trial Notification (CTN) clearance in Australia to initiate a first-in-human clinical trial for KIVU-305. KIVU-305 will enter clinical development as Kivu’s second ADC program and further validate the company’s differentiated approach to designing ADCs with improved stability, potency, and tolerability.

"Presenting these data at World ADC London while also securing Australian HREC approval and CTN clearance marks a significant milestone for Kivu as we advance our second ADC candidate into the clinic," said Mohit Trikha, Ph.D., President and Chief Operating Officer, Kivu Bioscience. "KIVU-305 reflects our focus on improving ADC stability and tumor exposure while minimizing free payload toxicity, and we look forward to evaluating its potential to deliver a differentiated treatment option for patients with CEACAM5-expressing cancers."

CEACAM5 is broadly expressed across multiple solid tumors, including colorectal, pancreatic, and non-small cell lung cancers, where high expression is associated with poor prognosis and reduced overall survival. Despite prior validation of CEACAM5-directed ADCs, toxicity related to payload release has limited therapeutic benefit, highlighting the need for next-generation designs with improved stability and a wider therapeutic index.

KIVU-305 is a next-generation CEACAM5-targeted ADC composed of a humanized antibody conjugated via site-specific GlycoConnect technology to a HydraSpace-linked SYNtecan E topoisomerase inhibitor payload. The molecule incorporates an Fc-silenced antibody and optimized DAR4 configuration designed to enhance plasma stability, reduce Fc-mediated immune activity, enable higher intact ADC tumor exposure, and lower circulating free payload levels.

Preclinical results presented at World ADC London demonstrated:

Selective nanomolar binding to CEACAM5-positive tumor cells with efficient internalization
Potent target-dependent cytotoxicity and meaningful bystander killing activity
Strong anti-tumor efficacy across multiple cell-line-derived and patient-derived xenograft models, including chemotherapy-resistant tumors
Favorable pharmacokinetics, high plasma stability, and low free payload concentrations
Encouraging tolerability in repeat dose studies in non-human primates
These findings support advancement of KIVU-305 into a Phase 1 study evaluating safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with advanced CEACAM5-expressing solid tumors.

About KIVU-305

KIVU-305 is a next-generation CEACAM5-targeted antibody-drug conjugate engineered to selectively bind tumor cells and deliver a potent topoisomerase inhibitor payload. Through site-specific conjugation, Fc-silencing, and optimized linker-payload design, KIVU-305 is designed to improve stability, reduce off-target toxicity, and potentially widen the therapeutic window in patients with advanced solid tumors.

(Press release, Kivu Bioscience, FEB 25, 2026, View Source [SID1234663014])

On February 25, 2026 Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, reported the pricing of its underwritten public offering of 17,647,058 shares of its common stock at a price to the public of $8.50 per share. The gross proceeds to Vir Biotechnology from the offering are expected to be $150 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Vir Biotechnology has granted the underwriters a 30-day option to purchase up to an additional 2,647,058 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are being sold by Vir Biotechnology. Closing of the offering is expected to occur on February 27, 2026, subject to customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI and Barclays are acting as book-running managers for the offering.

The shares described above are being offered pursuant to an automatically effective shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission, or the SEC, on November 3, 2023. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on February 24, 2026. The final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, by contacting: Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at [email protected]; Leerink Partners LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at [email protected]; Evercore Group L.L.C., Attn: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at [email protected]; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (888) 603-5847, or by email at [email protected]; or by accessing the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Vir Biotechnology, FEB 25, 2026, View Source [SID1234663013])